

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN 复星**

**復星國際有限公司**

**FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability under the Companies Ordinance)*

**(Stock Code: 00656)**

**VOLUNTARY ANNOUNCEMENT  
PARTICIPATION BY FOSUN PHARMA  
IN PRIVATIZATION OF CHINDEX**

Reference is made to the discloseable and connected transactions announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”, a subsidiary of Fosun International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and whose A shares are listed and traded on Shanghai Stock Exchange (Stock Code: 600196) and H shares are listed and traded on The Stock Exchange of Hong Kong Limited (Stock Code: 02196)) issued on the website of The Stock Exchange of Hong Kong Limited dated 17 February 2014 in relation to, among others, the proposed privatization of Chindex International, Inc. (“**Chindex**”).

Chindex, a company listed on the NASDAQ and an invested company of Fosun Industrial Co., Limited (“**Fosun Industrial**”, a wholly-owned subsidiary of Fosun Pharma), proposed to be delisted from the NASDAQ through privatization by merger. Fosun Industrial will participate in the privatization of Chindex by way of share contribution of 3,157,163 shares in Chindex (class A common stock) and cash contribution of not more than US\$193.74 million to Healthy Harmony Holdings L.P. (“**Healthy Harmony**”), which will wholly own Chindex upon completion of the privatization (the “**Proposed Transaction**”). Upon the completion of the Proposed Transaction, it is expected that the equity interests in Chindex indirectly held by Fosun Pharma will be increased from 17.45% up to maximum of 48.65%.

Chindex is an American healthcare company providing premium quality healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. The Group is optimistic about the long-term development of the healthcare industry. It is expected that the Proposed Transaction can help further strengthen the working capital of Chindex, expand its presence in the high-end healthcare services sector in the PRC, increase its business scale and improve profitability and can benefit the Group as a whole.

Shareholders of the Company and potential investors should note that the Proposed Transaction is subject to various conditions which may or may not be fulfilled. There is therefore no assurance that the Proposed Transaction will proceed. Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

Shanghai, the PRC, 17 February 2014

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Fan Wei; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.*